American Regent is pleased to announce the commercial launch and availability of Gvoke VialDx. Gvoke VialDx (glucagon injection) is a gastrointestinal motility inhibitor indicated for intravenous use as a diagnostic aid during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract in adult patients. The launch of Gvoke VialDx is the result of a partnership between American Regent and Xeris Pharmaceuticals. Under the terms of the agreement, Xeris will be responsible for product supply, and American Regent will be responsible for the commercialization of Gvoke VialDx in the U.S. Xeris Pharmaceuticals is a wholly owned subsidiary of Xeris Biopharma (XERS) Holdings.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XERS:
- Xeris Biopharma announces Orange Book listing of U.S. patent for Recorlev
- Xeris Pharmaceuticals Reports Record Revenue and Growth
- Xeris Pharmaceuticals: Undervalued Growth Potential Driven by Recorlev and XP-8121
- Xeris Biopharma assumed with a Buy at H.C. Wainwright
- Xeris Biopharma price target raised to $8 from $7 at Oppenheimer